5816results about "Inanimate material medical ingredients" patented technology

The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatological disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. The invention also relates to a method of treating a tar-responsive dermatological disorder by topically applying the composition to skin of a mammal, preferably a human, that is involved with the disorder.

The present invention provides one medicine composition for treating coronary heat disease ventricular premature beat based on the Chinese medicine theory of benefiting vital energy, nourishing Yin, promoting blood circulation, dredging meridian, clearing away heat-evil in the pericardium and tranquilizing. The medicine composition has 12 kinds of Chinese medicinal materials including ginseng, ophiopogon root, dogwood, red sage, common jujube seed, etc. The pharmacological test shows that the composite medicine capsule has obvious effect of preventing mouse's arrhythmia caused by CaCl2 and decreasing the sustained time of rat's arrhythmia caused by aconitine.

A composition for promoting the formation of clots in blood comprises a binder and a zeolite disposed in the binder, the zeolite having an adjusted calcium content. A method of forming a blood-clotting composition comprises the steps of providing a zeolite, combining the zeolite with a binder, and adjusting a calcium content of the zeolite to have an amount of calcium such that upon application of the composition to a wound, a heat of hydration is reduced and thereby heat transferred to the wound is reduced. A method of clotting blood flowing from a wound comprises the steps of applying a zeolite to the wound and maintaining the zeolite in contact with the wound for a predetermined amount of time. The zeolite preferably has an adjusted calcium content and is capable of producing a controllable blood clotting effect on the wound.

The invention relates to a Chinese medicinal preparation for treating a prostate disease, which is a medicament prepared from 70 raw material medicaments such as ginseng, deerhorn glue, medicinal indianmulberry root, common curculigo rhizome and the like. The medicament can be prepared into oral liquid, granules, powder, capsules, electuary, tablets or pills. A preparation method of the medicament comprises the following steps of: (1) preparing water extracting solution by the raw material medicaments; (2) preparing oral liquid by the water extracting solution; (3) drying, crushing and sieving the water extracting solution, and taking screening as medicinal extracting powder; and (4) preparing tablets, granules, pills or capsules from the medicinal extracting powder. The preparation method also can comprise the following steps of: (1) crushing and sieving the raw material medicaments, and taking the screening as medicinal powder; (2) disinfecting and sterilizing the medicinal powder to obtain raw powder; and (3) preparing tablets, granules, pills, electuary or capsules from raw powder. The adopted raw material medicaments are common Chinese medicaments, so the Chinese medicinal preparation has the advantages of low manufacturing cost, and nearly no toxic or side effects. The medicament has good curative effects on prostatitis, prostatic hypertrophy and prostatomegaly, and has obvious effect on prostate cancers.

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.

The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q₁₀ (CoQ₁₀), reduced CoQ₁₀, or mixtures thereof and oxygenated dibenzo-α-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and/or provide therapy to individuals at risk and/or under treatment for dysfunctions of energy metabolism, and specifically, for mitochondrial diseases.

The invention aims to provide a traditional Chinese medicine for treating apoplectic hemiplegia and general paralysis. The traditional Chinese medicine comprises the raw materials of dozens of animal medicines and plant medicines such as gardenia, white atractylodes rhizome, radix bupleuri, green tangerine peel, tangerine peel, peach kernel, almond, mastic, myrrh, rhizoma sparganii, rhizoma zedoariae, spatholobus stem, radix notoginseng, calamus, radix salviae miltiorrhizae, rhubarb, turmeric, buffalo horn, muscardine silkworm, cornu antelopis, ox gadfly, white grub, jiashu, eupolyphaga, earthworm, leech, succinum, scorpio, centipede, draconis sanguis, pearl, borneol, realgar, cinnabar, long-noded pit viper, black-tail snake, long-noded pit viper, cicada slough and the like. The medicines are pulverized and prepared into medicinal granules, tablets, oral liquid, honeyed pills, water-bindered pills and capsules. The traditional Chinese medicine is quantitatively taken on time and can be used for promoting blood circulation, relieving the stasis of blood, expanding the blood vessels, improving the blood circulation of the brain, inducing the functional recovery of the brain, regulating the function of each system of a human body comprehensively and reinforcing the stress resistance and the tolerance of the human body, so that the curative effect is good, the total effective rate reaches 100%, and the cure rate reaches 100%. The invention is suitable for various patients suffering from the apoplectic hemiplegia and the general paralysis.

The invention discloses a medicament for treating cerebral thrombus which comprises the following raw materials: white atractylodes rhizome, dried orange peel, root of red rooted saliva, gastrodia tuber, chrysanthemum morofolium ramat, earthworm, safflower, grassleaved sweetflag rhizome, Ligusticum wallichii, peach kernels, polygala root, gum benzoin, licorice root, liquidambar orientalis mill, pericarpium trichosanthis, selfheal, natural musk, wine-treated rhubarb, tortoise shell, natural cow-bezoar, turtle shell, wild chrysanthemum flower, wild jujuba seeds, rhizoma dioscoreae, arborviate seed, capsule of weeping forsythia, spicebush root, malt, medicated leaven, achyranthes and cyathula root, achyranthes root, stellaria root, Arisaema cum Bile, ginseng, scorpion, clerodendroa cyrtophyllum, red ginseng, astragalus root, clematis stem, root of American ginseng, Chinese angelica root, immature bitter orange, lilyturf root and pilose asiabell root.

The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.

The compounds of this invention have formula I:

wherein the variables are as defined herein.

The invention provides a lady health-care wine and a preparation method thereof. The health-care wine is prepared from angelica, hemlock parsley, radix paeoniae alba, prepared radix rehmanniae, raw radix rehmanniae, radix ophiopogonis, prepared fleece-flower root, lucid ganoderma, radix astragali, ginseng, rhizoma polygonati, poria with hostwood, polygala root, stir-fried spine date seed, deer fetus paste, antler, donkey-hide gelatin, glue of tortoise plastron, stir-fried eucommia, mistletoe, pawpaw, radix achyranthis bidentatae, broomrape, rhizoma drynariae, spatholobus stem, cassia bark, cornus officinalis, epimedium, Curculigo orchioides, saffron, Cordyceps, rhizoma cyperi, agilawood, Flos Caryophyllata, dalbergia wood, Turmeric Root-tuber, Rhizoma Zedoariae, cowherb seed, pseudo-ginseng, raw pollen typhae, pummelo pee, fingered citron, citron, raw rhubarb, fructus cannabis, bush-cherry seed, peach kernel, Chinese radish seed, semolina seed, cassia seed, Plantain seed, dodder, wolfberry fruit, raspberry, schisandra fruit, cherokee rose, Semen Euryales, gynostemma pentaphyllum, raw hawthorn, red rice, gastrodia tuber, kudzu root, chrysanthemum flower, calcined oyster and dragon bone, white spirit and yellow wine. The preparation method comprises the following steps: soaking the Chinese medicinal herbs in 50 vol% top-grade white spirit for 36 days (stirring every three days),and discarding the Chinese medicinal herbs after 36 days; and adding top-grade yellow wine (twice of white spirit), adding a right amount of honey (according to mouthfeel), sealing, and soaking for 36 days (stirring every three days) to obtain the lady health-care wine. When people drink 50ml of the health-care wine a day, the health-care wine can tonify the liver and kidney, recuperate yin and yang, invigorate qi, strengthen the bone, nourish the blood and refresh the brain.

The invention discloses a new traditional Chinese medicine composition for treating insomnia and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw Chinese medicinal herbal materials: cinnabar, nacre mother of pearl, cortex albiziae, semen boitae, tuber fleeceflower stem, polygala root, amber, fossil fragments, spina date seed, glossy ganoderma, shell of abalone, oyster, gastrodia elata, root of straight ladybell, ophiopogon japonicus, lucid asparagus, fruit of Chinese wolfberry, fushen, motherwort, Chinese angelica, radix paeoniae alba, cortex lycii radicis, agilawood, root of three-nerved spicebush, rhizoma cyperi and the like. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of insomnia, difficulty falling asleep, easy awakening, difficulty falling asleep after awakening, alternation of falling asleep and awakening, difficulty falling asleep all through the night, doldrums, slow response, fatigue, even vexation and the like, and has the advantages of accurate clinical treatment effect, remarkable treatment effect, low cost, basically no toxic or side effects, and the like.

The present invention relates to a biostimulatinq agent comprising natural minerals having ion-exchanges and sorption properties, and also a biologically active vegetable stock, the natural minerals including a clinoptylolite-heulandite zeolite containing not less than 92 wt % of clinoptylolite, and/or montmorillonite clay containing not less than 92 wt % of montmorillonite, and as the biologically active vegetable stock comprises wheat bran, rye bran, oats, Japanese laminaria, madder, birch fungus, and the like.The biostimulating agent of the present invention normalizes the mineral balance of the body, produces higher therapeutical effect, for example, in using it in case of intestinal tract diseases, aterosclerosis, urinary calculosis, produces an immune-modulating and tonic effect.

An antimicrobial hydrogel composition contains at least one antimicrobial silver salt; at least one viscosity-enhancing agent chosen from natural clay and synthetic clay; and at least one electrolyte. Methods of making the composition, methods of disinfecting, and methods of treating are also disclosed.

In a method of clotting blood in which the blood exhibits a reduced tendency to clot and may be from a person undergoing an anticoagulant therapy or having type A or B hemophilia or von Willebrand disease, a therapeutically effective amount of a composition comprising clay as the active ingredient is administered to a wound from which the blood emanates. Upon contacting the blood, this clay, which may be kaolin, bentonite, or any type of layered clay, causes the blood to clot. In a method of arresting blood flowing from a wound, a therapeutically effective amount of a composition comprising clay as the active ingredient is administered to the bleeding wound. In this method, the blood has a reduced tendency to clot and may be from a person undergoing an anticoagulant therapy or having at least one of hemophilia A or B or von Willebrand disease.

An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested/shown that C_20:5n-3 (and C_{22:6 n-3}) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

The present application is directed to a method for preparing a solution containing processed nicotine and beverages made according to such method. The beverage produced according to this method does not have the discernible taste, smell or appearance of nicotine.

The invention discloses a traditional Chinese medicine combination and a preparation method thereof for dysentery treatment; the traditional Chinese medicine combination mainly includes the following raw medicines: the rhizome of Chinese goldthread, bighead atractylodes rhizome, rhizoma atractylodis, mangnolia officinalis, medicated leaven, sunburn frankincense, sunburn myrrh, rhizoma alismatis, plantain seed, fructus evodiae, dried tangerine, angelica, white paeony root, scutellaria baicalensis, oyster, red halloysite, starwort root, rhizoma cyperi, gorgon fruit, Chinese yam, drgon's bones, radix sophorae flavescentis, ash bark and codonopsis pilosula and the like. The traditional Chinese medicine combination can be prepared into any type of common oral preparation according to the conventional traditional Chinese medicine preparation method. The invention can significantly improve the symptoms of diarrhea, dysentery, bellyache, tenesmus, dyspepsia, difficult diet and loss of appetite, and also has definite clinical curative effect, significant curative and quick effect. As the traditional Chinese medicine combination basically combines medicinal and edible medicine sources specified in the National Formulary, the traditional Chinese medicine combination has low cost and basically has no toxic and side effect.

The present invention relates to one kind of Chinese medicine preparation for curing gastropathy radically. The Chinese medicine preparation is prepared with 29 kinds of Chinese medicinal materials, including astragalus root, corydalis tuber, cuttlebone, chicken's gizzard membrane, white atractylodes rhizome, etc. It has obvious curative effect on various kinds of chronic gastritis, antrum gastritis, digestive track ulcer, etc and no toxic side effect, and can prevent gastric cancer and gastric mucosa pathology.

The invention discloses an anti-human CLDN18.2 antibody as well as an antigen binding fragment and a medical application thereof. Specifically, the present invention relates to a murine antibody comprising a CDR region of the anti-human CLDN18.2 antibody, a chimeric antibody and a humanized antibody, a fully humanized antibody, an antibody-dependent cytotoxicity (ADCC) comprising the antibody andthe antigen binding fragment thereof, complement dependent cytotoxicity (CDC), the killing effect on CLDN18.2 positive cells, the effect of inhibiting the growth of CLDN18.2 positive tumors, the in-vivo drug effect, a medicine containing the anti-human CLDN18.2 antibody and the antigen binding fragment thereof, a composition of the medicine thereof, and an application of the medicine in tumor treatment, in particular to treatment of CLDN18.2 positive tumor patients..

Dryness of keratin materials, in particular dryness of the skin, and especially disorders associated with dry and/or hyposeborrheic skin are treated by administering to individuals afflicted therewith, thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured in a medium which includes at least one non-sulfurous mineral and/or thermal water, e.g., an extract derived from the bacterium Vitreoscilla filiformis, in particular the strain ATCC 15551, cultured in a medium enriched with water from La Roche Posay.